A Better Tomorrow with HanAll

Innovative Therapeutics to Address Unmet Medical Needs of Patients

Developing Innovations for Healthier,
Longer lives for Patients

Committed to Pioneering Next
Generation Technology

Our company pledges to make meaningful contributions to patients by
improving current medical practices. We believe in science, take risks for
innovations, learn from mistakes, and humbly serve the patients.
HanAll
News
Latest News
NEWS

HanAll Biopharma Reports Q3 2024 Financial Results and Prov..

-HanAll records revenue of 36.8 billion KRW in the third quarter, with an opera..

2024.11.01
NEWS

HanAll Biopharma Reports Q2 2024 Financial Results and Provi..

- HanAll reports strong financial performance with second quarter total revenue..

2024.07.26
NEWS

HanAll Biopharma Appoints Christopher W Slavinsky as Chief B..

HanAll Biopharma (KRX: 009420.KS) announced today the appointment of Christophe..

2024.07.15
NEWS

HanAll Biopharma Signs Licensing Agreement with Turn Biotech..

- Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Agin..

2024.05.28
NEWS

HanAll Biopharma Announces Initiation of Phase III Randomize..

- HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and ..

2024.05.07
NEWS

HanAll Biopharma Reports Q1 2024 Financial Results and Provi..

- Delivered solid performance to start 2024, with record-breaking first quarter..

2024.04.30
NEWS

HanAll Biopharma awards 2024 National Industry Awards for Re..

- Gains recognition for contributing to the development of the biopharma indust..

2024.04.22
NEWS

HanAll Biopharma Reports Full-Year 2023 Financial Results an..

- Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales gr..

2024.03.21
pipeline
HanAll is primed to develop innovative,
impactful therapies to address unmet medical needs
Tanfanercept
A novel, topical, anti-TNF alpha protein drug for the treatment
of inflammatory eye diseases including dry eye disease
VIEW MORE
Batoclimab
A novel, anti-FcRn antibody for the treatment
of autoimmune diseases
VIEW MORE
Immuno-oncology
Next-generation immune checkpoint inhibitor
VIEW MORE